Safety of ilunocitinib tablets (Zenrelia™) after once daily oral administration in dogs
Abstract Background Ilunocitinib is a new molecular entity of the Janus kinase inhibitor (JAKi) class for the treatment and control of symptoms of allergic skin disease conditions, such as pruritus and skin lesions in dogs. This laboratory study with ilunocitinib tablets (Zenrelia™, Elanco) investig...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-03-01
|
| Series: | BMC Veterinary Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12917-025-04579-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|